← Browse by Condition
Medical Condition

advanced pancreatic adenocarcinoma

Total Trials
2
Recruiting Now
2
Trial Phases
Phase 1

ClinicalMetric tracks all active clinical trials for advanced pancreatic adenocarcinoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — advanced pancreatic adenocarcinoma Clinical Trials

How many clinical trials are currently recruiting for advanced pancreatic adenocarcinoma?
ClinicalMetric currently tracks 2 actively recruiting clinical trials for advanced pancreatic adenocarcinoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 2. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for advanced pancreatic adenocarcinoma?
advanced pancreatic adenocarcinoma research spans Phase 1 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a advanced pancreatic adenocarcinoma clinical trial?
Eligibility criteria for advanced pancreatic adenocarcinoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
1
Top Sponsors
City of Hope Medical Center 1 trial
University of Rochester 1 trial

Recruiting Clinical Trials

NCT06454383 Phase 1
Recruiting
Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer
Enrollment
19 pts
Location
United States
Sponsor
City of Hope Medical Center
View Trial →
NCT06073431
Recruiting
LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia
Enrollment
800 pts
Location
United States
Sponsor
University of Rochester
View Trial →

Related Conditions

stage iv pancreatic cancer ajcc v8 (2) stage iii pancreatic cancer ajcc v8 (1) unresectable pancreatic ductal adenocarcinoma (1) advanced colorectal carcinoma (1) advanced lung non small cell carcinoma (1) stage iv colorectal cancer ajcc v8 (1) stage iv lung cancer ajcc v8 (1) unresectable colorectal carcinoma (1) unresectable lung non small cell carcinoma (1) unresectable pancreatic adenocarcinoma (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology